PROTAC BRD9 Degrader-7

• UNSPSC Description:

  PROTAC BRD9 Degrader-7 is an orally active and selective degrader of BRD9 with a DC50 of 1.02 nM. PROTAC BRD9 Degrader-7 has superior oral activity with a Cmax of 3436.95 ng/mL[1].

• Target Antigen:

  PROTACs

• Type:

  Reference compound

• Related Pathways:

  PROTAC

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/protac-brd9-degrader-7.html

• Purity:

  99.29

• Solubility:

  DMSO : 70 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(N(C)C=C1C2=CC(OC)=C(CN3CCN(C4=CC=C5C(C(N(C6C(NC(CC6)=O)=O)C5=O)=O)=C4)CC3)C(OC)=C2)C7=C1C=CC=C7

• Molecular Weight:

  649.69

• References & Citations:

  [1]Jingyu Zhang, et al. Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia, European Journal of Medicinal Chemistry, Volume 262, 2023, 115872.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported